Institutional members access full text with Ovid®

Share this article on:

Patch Tests With Fragrance Mix II and Its Components

Pónyai, Györgyi MD, PhD*; Németh, Ilona*; Altmayer, Anita MD; Nagy, Gabriella MD; Irinyi, Beatrix MD, PhD§; Battyáni, Zita MD, PhD∥¶; Temesvári, Erzsébet MD, PhD*on behalf of the Hungarian Contact Dermatitis Group

doi: 10.1097/DER.0b013e31824a6104

Background Fragrance mix II (FM II) was initiated to detect contact hypersenstitivity (CH) to fragrances that could not have been identified previously.

Objective The aim of this multicenter study was to map the frequency of CH to FM II and its components in Hungary.

Methods Six centers participated in the survey from 2009 to 2010. A total off 565 patients (434 women and 131 men) with former skin symptoms provoked by scented products were patch tested. The tests were performed with Brial GmbH D-Greven allergens. In the environmental patch test series, FM II, FM I, Myroxylon pereirae, colophonium, wood-tar mix, propolis, and sesquiterpene lactone mix were tested as fragrance allergens. The FM II components (citral, farnesol, coumarin, citronellol, α-hexyl-cinnamaldehyde, and hydroxy-isohexyl-3-cyclohexene-carboxaldehyde [Lyral]) were also tested.

Results Contact hypersenstitivity to any fragrances was detected in 28.8%, to FM II in 17.2% of the patients. Contact hypersenstitivity to hydroxy-isohexyl-3-cyclohexene-carboxaldehyde was observed in 7.3%, to coumarin in 5.1%, to α-hexyl-cinnamaldehyde in 3.5%, to citral in 3.4%, to farnesol in 2.5%, and to citronellol in 1.2%. Of the FM II–positive cases, 48.4% showed isolated CH reaction.

Conclusions The frequency of CH to FM II is 17.2% in the tested, selected Hungarian population. The CH to FM II and its components could not have been revealed without the present test materials.

From the *Department of Dermatology, Venerology, and Dermato-oncology, Semmelweis University, Budapest; †Department of Dermatology and Allergy of the Szent-Györgyi Albert Clinical Centre, Szeged University of Sciences, Szeged; ‡Centre of Dermatology, Semmelweis Medical Centre of Miskolc, Miskolc; §Department of Dermatology, Centre for Medicine and Medical Sciences, Faculty of General Medicine, University of Debrecen, Debrecen; ∥Department of Dermatology, Venerology and Dermato-oncology, Pécs Medical University, Pécs; and ¶Department of Dermatology, Kaposi Mór Teaching Hospital, Kaposvár, Hungary.

Address reprint requests to Györgyi Pónyai, MD, PhD, Department of Dermatology, Venerology, and Dermato-oncology, Semmelweis University, Budapest, Hungary. E-mail:

The authors have no funding or conflicts of interest to declare.

©2012American Contact Dermatitis Society, All Right Reserved
You currently do not have access to this article

To access this article:

Note: If your society membership provides full-access, you may need to login on your society website